Twist Bioscience: Investor Ready

  • TWST (Twist Bioscience Corp.) is set to have their first full year earning report today.

  • What are investors looking for?

  • Is it a buy in their competitive market?

TWST (Twist Bioscience Corp., $19.11) is a synthetic biology company that creates single-stranded and double-stranded DNA synthesis platforms to industrialize through biological engineering. The company also has a range of other products and services such as genetic testing, antibody library for drug discovery, and synthetic genes for cloning development.

(See bottom of article for Honest Review)

IPO (Initional Public Offering)

TWST opened it’s IPO on October 31st, 2018 with an opening share price of $14.00 in the NASDAQ Global Select Market. Despite the normal volatility of the new IPO, investors have their eye on TWST because healthcare related startups are currently in high demand

You can follow Twist Bioscience on Twitter.

According to, the global synthetic biology market is forecast to reach over $38 billion by the year 2020. Though this market is undergoing extensive research, TWST has opportunities to discover new treatments for genetic diseases, DNA storage, and genetic testing for early diagnosis. It’s apparent that there is plenty of expand for TWST to grow in the healthcare sector, however what does the company offer for it’s investors?

TWST currently delivers no dividends to its shareholders but is currently at a fair stock price under $20 (before opening bell of 12/19/18). With a 52-week high of $34.46 and low of $12.38, investors may have a buying opportunity if they are feeling lucky. There is a consensus EPS (earning per share) forecast of -$0.79 and regarding financials the company has plenty of debt. 

Earnings Report 12/19

The full year earnings report will be held today via conference call and audio webcast at 4:30pm eastern time. Financial results will be available for investors prior to the call on the company website at in “company” tab. You can listen to the call at (866) 688-0947 domestic or (409) 217-8781 international with conference ID 

Honest Opinion

In my opinion, I believe TWST has plenty of room to grow. DNA sequencing and genetic testing will be very popular towards 2020 and with commonly used brands such as AncestryDNA and 21andMe, TWST may have a chance to succeed long-term. Though the company is under a pending lawsuit from Agilent (A), I will be paying close attention to how they manage their profits and R&D (research and development) expenses in their earnings review. The company’s largest customers are Microsoft (MSFT), Illumnia (ILMN), Applied Materials (AMAT) and private company start-up Ginko Bioworks. If the individual investor is completely confident in his or her investment choice with this company, he she is neither right nor wrong.

Please see About Me & Disclaimer for additional information about Black Tea.

Closing Disclaimer:

I am not a certified professional, nor responsible for any of your gains or loses. I’m simply a passionate stock investor who loves to share my experience with other women/men who want to learn general information about the market. May I encourage you to study and evaluate before you make any purchase or sale in the stock market. We are a participant in the Amazon Affiliate Services LLC program, an affiliate advertising program designed to provide means for us to earn fees by linking to and affiliated sites.

Additional Disclaimer:

This blog is not a paid advertisement from any financial institution or the owners from Twist Bioscience and I was not paid prior to writing this post.

Information Attained:,,,